Morgan Stanley Reiterates Buy Rating on Mirum Pharmaceuticals
Morgan Stanley maintains its buy rating with a $150 target for Mirum Pharmaceuticals, a 48.51% upside from the current price.
Key Points
- Morgan Stanley analyst Michael Ulz reiterated a buy rating for Mirum Pharmaceuticals with a target price of $150 on June 11, 2026.
- Morgan Stanley's $150 price target implies 48.51% upside from Mirum Pharmaceuticals, Inc.'s ($MIRM) current $101 share price.
- Mirum Pharmaceuticals, trading at $99.52, has a market cap of $6.06 billion and a 52-week high of $114.99.
- Institutional activity includes Frazier Life Sciences Management adding 884,563 shares, while State Street Corp reduced its holdings by 199,711 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Morgan Stanley analyst Michael Ulz reiterated a buy rating on Mirum Pharmaceuticals, Inc. (NasdaqGM: MIRM) on June 11, 2026. Ulz set a target price of $150 for the biopharmaceutical company, which focuses on treatments for rare diseases. Mirum's stock traded at $99.52 as of this report.
Other Institutional Activity in Mirum Pharmaceuticals
Several other institutional investors have been active in Mirum Pharmaceuticals. Frazier Life Sciences Management grew its holdings by 884,563 shares, reaching a total of 7,679,684 shares worth about $709.4 million. Janus Henderson Group added 880,505 shares, ending with 6,945,813 shares valued at $641.8 million. BlackRock, Inc. increased its stake by 201,244 shares to 3,846,530 shares, valued at $355.3 million. On the other hand, State Street Corp reduced its holdings by 199,711 shares, leaving it with 1,944,281 shares worth $179.6 million.
Mirum Pharmaceuticals, Inc. Stock Up 3.6%
Shares of Mirum Pharmaceuticals are trading near $99.52. The company has a market capitalization of approximately $6.06 billion. Mirum's forward P/E ratio is not meaningful due to its lack of profitability, and it has a beta of 0.506. The stock's 52-week range is between $47.89 and $114.99, with a 50-day moving average of $98.07 and a 200-day moving average of $85.59. The current ratio stands at 2.09, and its debt-to-equity ratio is 133.52.
$MIRM price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Mirum Pharmaceuticals reported revenue of $569.6 million, reflecting a growth rate of 43.3%. However, the company posted a net margin of -140.2% and a return on equity of -335.8%. The next earnings report is expected on May 6, 2026.
Insider Buying and Selling at Mirum Pharmaceuticals, Inc.
Recent insider activity includes CFO Eric Bjerkholt purchasing 2,393 shares on June 9, 2026, at $26.49 per share. On the same day, he also sold 2,393 shares as part of a planned transaction. Additionally, on June 8, 2026, Bjerkholt sold 5,000 shares at an average price of $93.82 under a Rule 10b5-1 plan. President and COO Peter Radovich bought and sold 16,988 shares on June 5, 2026.
Analysts Set New Price Targets
On June 11, 2026, Morgan Stanley maintained its buy rating with a $150 price target. Citigroup initiated coverage on June 2, 2026, with a buy rating and a $145 target. Wolfe Research also initiated coverage with a buy rating and a similar target on May 19, 2026. The consensus rating is a strong buy, with a mean target price of $144.93 based on 14 analyst opinions.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. is a biotech company headquartered in Foster City, California, specializing in therapies for rare and orphan diseases. Its main product, LIVMARLI, treats cholestatic pruritus in Alagille syndrome. The company also markets Cholbam and Chenodal for bile acid disorders and gallbladder stones, and is developing treatments for other diseases. Mirum collaborates with several major pharmaceutical companies and was founded in 2018.
Bottom Line
Morgan Stanley's reiteration of a buy rating with a $150 target reflects ongoing confidence in Mirum Pharmaceuticals' potential. Investors keep a close eye on such analyst actions, though it's important to remember that these ratings are based on past data and projections. As always, 13F filings and analyst ratings provide a snapshot of sentiment but don't guarantee future performance.
Get Mirum Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $MIRM, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.